Steady‐State Ceftazidime‐Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration-Reference-Cited by-同舟云学术

Steady‐State Ceftazidime‐Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration

Published:2019-10-31 Issue:12 Volume:39 Page:1216-1222
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Soukup Paige¹,Faust Andrew C.¹^ORCID,Edpuganti Vindhya²³,Putnam William C.²³,McKinnell James A.⁴⁵

Affiliation:

1. Department of Pharmacy Texas Health Presbyterian Hospital of Dallas Dallas Texas

2. Department of Pharmacy Practice Jerry H. Hodge School of Pharmacy Texas Tech University Health Sciences Center Dallas Texas

3. Clinical Pharmacology and Experimental Therapeutics Center Jerry H. Hodge School of Pharmacy Texas Tech University Health Sciences Center Dallas Texas

4. David Geffen School of Medicine University of California Los Angeles California

5. Infectious Disease Clinical Outcome Research Unit (ID‐CORE) Los Angeles Biomedical Research Institute at Harbor‐UCLA Torrance California

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2338

Reference17 articles.

1. Avycaz (ceftazidime/avibactam) [prescribing information].Irvine CA:Allergan USA Inc; April2019.

2. Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?

3. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients

4. Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam;Antimicrobial Agents and Chemotherapy;2024-09-04

2. Pharmacokinetic parameters of CAZ–AVI in the normal lung and in models of pneumonia: lessons for treatment optimization in critical care;Journal of Chemotherapy;2024-01-30

3. Ceftazidime-avibactam induced renal disorders: past and present;Frontiers in Pharmacology;2024-01-22

4. Pharmacokinetic of ceftazidime‐avibactam in a critically ill patient under high‐volume continuous venovenous haemodiafiltration: A first paediatric case report;British Journal of Clinical Pharmacology;2024-01-15

5. Clinical efficacy of ceftazidime/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa;International Journal of Antimicrobial Agents;2024-01